A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1 (steroid receptor coactivator 1)
Lv. Nazareth et al., A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1 (steroid receptor coactivator 1), MOL ENDOCR, 13(12), 1999, pp. 2065-2075
Androgen ablation therapy is a primary treatment for advanced prostate canc
er, but tumors become refractive to therapy. Consequently, the role of the
androgen receptors (ARs) and of mutations in the AR in prostate cancer has
been a subject of much concern. In the course of analyzing tumors for mutat
ions, we identified a somatic mutation that substitutes tyrosine for a cyst
eine at amino acid 619 (C619Y), which is near the cysteines that coordinate
zinc in the DNA binding domain in the AR. The mutation was re-created in a
wild-type expression vector and functional analyses carried out using tran
sfection assays with androgen-responsive reporters. The mutant is transcrip
tionally inactive and unable to bind DNA. In response to ligand treatment,
AR619Y localizes abnormally in numerous, well circumscribed predominantly n
uclear aggregates in the nucleus and cytoplasm. Interestingly, these aggreg
ates also contain the bulk of the coexpressed steroid receptor coactivator
SRC-1, suggesting, in analogy to AR in spinal bulbar muscular atrophy, that
this mutant may alter cellular physiology through sequestration of critica
l proteins. Although many inactivating mutations have been identified in an
drogen insensitivity syndrome patients, to our knowledge, this is the first
characterization of an inactivating mutation identified in human prostate
cancer.